In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

A novel Rag2-/- c-/--xenograft model of human CLL

(2009) M. T. S. Bertilaccio et al.   BLOOD

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

(2009) J. C. Byrd et al.   BLOOD

The promise and potential pitfalls of chimeric antigen receptors

(2009) Michel Sadelain et al.   CURRENT OPINION IN IMMUNOLOGY

Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”

(2009) Gianpietro Dotti et al.   HUMAN GENE THERAPY

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

(2008) C. Quintarelli et al.   BLOOD

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD